Suppr超能文献

逍遥散方剂辅助治疗并加强乳腺癌术后护理。

Xiaoyaosan formula augments adjuvant therapy and enhances postoperative breast cancer care.

作者信息

Wang Chao, Yin Lianfang

机构信息

Department of Chinese Medicine, The First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui, China.

出版信息

Front Pharmacol. 2024 Aug 9;15:1388646. doi: 10.3389/fphar.2024.1388646. eCollection 2024.

Abstract

INTRODUCTION

Xiaoyaosan (XYS), a traditional Chinese formula, not only has good antitumor effects but also attenuates distress, anorexia, and quality of life (QoL) by regulating neurology, the microbiota, immunology, and oxidative stress. This study aimed to assess the effect of XYS on QoL, psychological pressure, and spiritual well-being in breast cancer patients undergoing adjuvant chemotherapy.

METHODS

This prospective cohort study enrolled 176 postoperative breast cancer patients who received adjuvant chemotherapy combined with (n = 81) or without (n = 95) XYS for comparison. The Quality-of-Life Questionnaire Core-30 (QLQ-C30), Hospital Anxiety and Depression Scale (HADS), University of California Los Angeles (UCLA-LS), and Functional Assessment of Chronic Illness Therapy-Spiritual Well-being (FACIT-Sp) scores were evaluated before adjuvant chemotherapy (T) and after the first (T), second (T), third (T), and fourth cycles (T) of adjuvant chemotherapy.

RESULTS

XYS improved the QLQ-C30 score at T ( = 0.043), T ( = 0.021), and T ( = 0.040) and the QLQ-C30 score at T ( = 0.027); moreover, XYS attenuated the QLQ-C30 score at T ( = 0.040), T ( = 0.023), and T ( = 0.027). Regarding distress, XYS reduced the HADS-anxiety score at T ( = 0.010), T ( = 0.025), and T ( = 0.019) and the HADS-defined anxiety score at T ( = 0.038). XYS also decreased the HADS-depression score at T ( = 0.016), T ( = 0.018), and T ( = 0.017) and the HADS-defined depression rate at T ( = 0.047), T ( = 0.012), and T ( = 0.013). In addition, XYS decreased the UCLA-LS at T ( = 0.023) but enhanced the FACIT-Sp at T ( = 0.029) and T ( = 0.026). Furthermore, after adjustment via propensity score matching, most of the significant findings remained.

DISCUSSION

The addition of XYS to adjuvant chemotherapy improved QoL, psychological health, and spiritual well-being in breast cancer patients.

摘要

引言

逍遥散(XYS)是一种传统中药方剂,不仅具有良好的抗肿瘤作用,还能通过调节神经、微生物群、免疫和氧化应激来减轻痛苦、厌食和改善生活质量(QoL)。本研究旨在评估逍遥散对接受辅助化疗的乳腺癌患者的生活质量、心理压力和精神健康的影响。

方法

这项前瞻性队列研究纳入了176例术后乳腺癌患者,其中81例接受辅助化疗联合逍遥散,95例仅接受辅助化疗作为对照。在辅助化疗前(T)以及辅助化疗的第1(T)、第2(T)、第3(T)和第4周期(T)后,评估生活质量问卷核心30项(QLQ-C30)、医院焦虑抑郁量表(HADS)、加利福尼亚大学洛杉矶分校孤独量表(UCLA-LS)以及慢性病治疗功能评估-精神健康(FACIT-Sp)评分。

结果

逍遥散提高了T时(P = 0.043)、T时(P = 0.021)和T时(P = 0.040)的QLQ-C30评分以及T时(P = 0.027)的QLQ-C30评分;此外,逍遥散降低了T时(P = 0.040)、T时(P = 0.023)和T时(P = 0.027)的QLQ-C30评分。关于痛苦,逍遥散降低了T时(P = 0.010)、T时(P = 0.025)和T时(P = 0.019)的HADS焦虑评分以及T时(P = 0.038)的HADS定义的焦虑评分。逍遥散还降低了T时(P = 0.016)、T时(P = 0.018)和T时(P = 0.017)的HADS抑郁评分以及T时(P = 0.047)、T时(P = 0.012)和T时(P = 0.013)的HADS定义的抑郁率。此外,逍遥散降低了T时(P = 0.023)的UCLA-LS评分,但提高了T时(P = 0.029)和T时(P = 0.026)的FACIT-Sp评分。此外,通过倾向得分匹配进行调整后,大多数显著结果仍然存在。

讨论

辅助化疗中加用逍遥散可改善乳腺癌患者的生活质量、心理健康和精神健康。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e502/11344260/1276f2e8c005/fphar-15-1388646-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验